SARS-CoV-2 - Baricitinib - Therapeutic Candidates

SARS-CoV-2 - Baricitinib - Therapeutic Candidates


Like ruxolitinib, baricitinib (OLUMIANT) is an inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) which are tyrosine kinases involved in JAK signaling pathways. Baricitinib is a reversible and selective inhibitor and is indicated in the treatment of moderate to severe active rheumatoid arthritis for its anti-inflammatory effect. It is a second-line therapy, i.e., used after failure of conventional disease-modifying therapies. It can be used alone or in combination with methotrexate (MTX).
A clinical study on the efficacy and safety of baricitinib for the treatment of Covid-19 has begun. The anti-inflammatory activity of this drug may have a potential beneficial effect in the treatment of Covid-19. The use of baritinicib therapy may limit the cytokine release syndrome associated with Covid-19 and may be useful because it acts against a wide range of cytokines.

Cat#
Description
Size
Price Excl. VAT
HY-15315A-100mg
 100mg 
HY-15315A-5mg
 5mg 
HY-15315-10mg
 10mg 
HY-15315-5mg
 5mg 
HY-15315-S
 0,5-1mg 
HY-15315-50mg
 50mg 
HY-15315A-1mL
 10mM/1mL 
HY-15315A-10mg
 10mg 
HY-15315A-S
 0,5-1mg 
HY-15315-100mg
 100mg 
HY-15315A-50mg
 50mg 
HY-15315-1mL
 10mM/1mL 
A11329-10mM-D
 10mM*1mLinDMSO 
M2039-10mg
 10 mg 
M2039-50mg
 50 mg 
2841-10
 10mg 
2841-50
 50mg 
2842-10
 10mg 
2842-50
 50mg 
SKP3158-10
 10mg 
SKP3158-100
 100mg 
SKP3158-25
 25mg 
SKP3158-5
 5mg 
SKP3158-50
 50mg 
B118690-10mg
 10mg 
B118690-1mg
 1mg 
B118690-25mg
 25mg 
B118690-50mg
 50mg 
B118690-5mg
 5mg 
AOB87724-100
 100mg 
263660-100mg
 100mg 
263660-250mg
 250mg 
Number of results per page : 10 50 250